ICON PLC (ICLR) Stock Fundamental Analysis
USA - NASDAQ:ICLR - IE0005711209 - Common Stock
179.43 USD
+4.22 (+2.41%)
179.43 USD
0 (0%)
Taking everything into account, ICLR scores 5 out of 10 in our fundamental rating. ICLR was compared to 55 industry peers in the Life Sciences Tools & Services industry. ICLR has an average financial health and profitability rating. ICLR has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ICLR had positive earnings in the past year.
In the past year ICLR had a positive cash flow from operations.
In the past 5 years ICLR has always been profitable.
In the past 5 years ICLR always reported a positive cash flow from operatings.
1.2 Ratios
ICLR has a Return On Assets of 4.78%. This is in the better half of the industry: ICLR outperforms 76.36% of its industry peers.
Looking at the Return On Equity, with a value of 8.31%, ICLR is in the better half of the industry, outperforming 76.36% of the companies in the same industry.
With a decent Return On Invested Capital value of 6.57%, ICLR is doing good in the industry, outperforming 74.55% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ICLR is significantly below the industry average of 15.96%.
The 3 year average ROIC (5.80%) for ICLR is below the current ROIC(6.57%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.78% | ||
| ROE | 8.31% | ||
| ROIC | 6.57% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
1.3 Margins
ICLR's Profit Margin of 9.82% is fine compared to the rest of the industry. ICLR outperforms 72.73% of its industry peers.
ICLR's Profit Margin has declined in the last couple of years.
The Operating Margin of ICLR (14.43%) is better than 78.18% of its industry peers.
ICLR's Operating Margin has been stable in the last couple of years.
With a Gross Margin value of 28.65%, ICLR is not doing good in the industry: 76.36% of the companies in the same industry are doing better.
ICLR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.43% | ||
| PM (TTM) | 9.82% | ||
| GM | 28.65% |
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ICLR is destroying value.
The number of shares outstanding for ICLR has been reduced compared to 1 year ago.
The number of shares outstanding for ICLR has been increased compared to 5 years ago.
The debt/assets ratio for ICLR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.15 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of ICLR (2.15) is comparable to the rest of the industry.
The Debt to FCF ratio of ICLR is 3.45, which is a good value as it means it would take ICLR, 3.45 years of fcf income to pay off all of its debts.
ICLR has a Debt to FCF ratio of 3.45. This is in the better half of the industry: ICLR outperforms 76.36% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that ICLR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.35, ICLR is in line with its industry, outperforming 47.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 3.45 | ||
| Altman-Z | 2.15 |
ROIC/WACC0.8
WACC8.17%
2.3 Liquidity
A Current Ratio of 1.29 indicates that ICLR should not have too much problems paying its short term obligations.
ICLR has a worse Current ratio (1.29) than 81.82% of its industry peers.
ICLR has a Quick Ratio of 1.29. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
ICLR has a Quick ratio of 1.29. This is in the lower half of the industry: ICLR underperforms 72.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
ICLR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.36%.
The Earnings Per Share has been growing by 15.23% on average over the past years. This is quite good.
The Revenue has decreased by -2.91% in the past year.
The Revenue has been growing by 24.17% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%
3.2 Future
ICLR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.25% yearly.
ICLR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.36% yearly.
EPS Next Y-3.09%
EPS Next 2Y1.71%
EPS Next 3Y4.15%
EPS Next 5Y7.25%
Revenue Next Year-3.49%
Revenue Next 2Y-1.07%
Revenue Next 3Y1.05%
Revenue Next 5Y2.36%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.56 indicates a correct valuation of ICLR.
Compared to the rest of the industry, the Price/Earnings ratio of ICLR indicates a rather cheap valuation: ICLR is cheaper than 96.36% of the companies listed in the same industry.
ICLR's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.41.
Based on the Price/Forward Earnings ratio of 12.39, the valuation of ICLR can be described as correct.
Based on the Price/Forward Earnings ratio, ICLR is valued cheaper than 94.55% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.88, ICLR is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.56 | ||
| Fwd PE | 12.39 |
4.2 Price Multiples
ICLR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ICLR is cheaper than 100.00% of the companies in the same industry.
ICLR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICLR is cheaper than 92.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.1 | ||
| EV/EBITDA | 10.73 |
4.3 Compensation for Growth
The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.89
EPS Next 2Y1.71%
EPS Next 3Y4.15%
5. Dividend
5.1 Amount
ICLR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
179.43
+4.22 (+2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners96.39%
Inst Owner Change-2.94%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap13.95B
Analysts79.2
Price Target220.12 (22.68%)
Short Float %3.04%
Short Ratio1.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.05%
Min EPS beat(2)-0.34%
Max EPS beat(2)0.23%
EPS beat(4)1
Avg EPS beat(4)-3.93%
Min EPS beat(4)-14.41%
Max EPS beat(4)0.23%
EPS beat(8)1
Avg EPS beat(8)-2.35%
EPS beat(12)3
Avg EPS beat(12)-1.69%
EPS beat(16)6
Avg EPS beat(16)-1.11%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-2.61%
Max Revenue beat(2)-0.23%
Revenue beat(4)0
Avg Revenue beat(4)-2.78%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-0.23%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)0
Avg Revenue beat(12)-2.36%
Revenue beat(16)0
Avg Revenue beat(16)-2.13%
PT rev (1m)-0.68%
PT rev (3m)20.94%
EPS NQ rev (1m)-0.84%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)0.32%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)-0.78%
Revenue NQ rev (3m)0.8%
Revenue NY rev (1m)-0.45%
Revenue NY rev (3m)0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.56 | ||
| Fwd PE | 12.39 | ||
| P/S | 1.72 | ||
| P/FCF | 14.1 | ||
| P/OCF | 12.08 | ||
| P/B | 1.46 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.73 |
EPS(TTM)13.23
EY7.37%
EPS(NY)14.48
Fwd EY8.07%
FCF(TTM)12.73
FCFY7.09%
OCF(TTM)14.86
OCFY8.28%
SpS104.02
BVpS122.86
TBVpS-38.32
PEG (NY)N/A
PEG (5Y)0.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.78% | ||
| ROE | 8.31% | ||
| ROCE | 8.31% | ||
| ROIC | 6.57% | ||
| ROICexc | 6.76% | ||
| ROICexgc | 82.41% | ||
| OM | 14.43% | ||
| PM (TTM) | 9.82% | ||
| GM | 28.65% | ||
| FCFM | 12.23% |
ROA(3y)3.74%
ROA(5y)4.36%
ROE(3y)6.96%
ROE(5y)8.15%
ROIC(3y)5.8%
ROIC(5y)6.92%
ROICexc(3y)5.97%
ROICexc(5y)8.67%
ROICexgc(3y)88.82%
ROICexgc(5y)90.84%
ROCE(3y)7.34%
ROCE(5y)8.76%
ROICexcg growth 3Y-4.45%
ROICexcg growth 5Y-5.01%
ROICexc growth 3Y27.99%
ROICexc growth 5Y-24.17%
OM growth 3Y9.91%
OM growth 5Y-0.95%
PM growth 3Y50.65%
PM growth 5Y-6.44%
GM growth 3Y2.3%
GM growth 5Y-0.09%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 3.45 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 43.25% | ||
| Cap/Sales | 2.05% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.49% | ||
| Profit Quality | 124.6% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 2.15 |
F-Score5
WACC8.17%
ROIC/WACC0.8
Cap/Depr(3y)27.79%
Cap/Depr(5y)38.09%
Cap/Sales(3y)1.87%
Cap/Sales(5y)1.83%
Profit Quality(3y)130.43%
Profit Quality(5y)205.36%
High Growth Momentum
Growth
EPS 1Y (TTM)-5.36%
EPS 3Y13.76%
EPS 5Y15.23%
EPS Q2Q%-13.07%
EPS Next Y-3.09%
EPS Next 2Y1.71%
EPS Next 3Y4.15%
EPS Next 5Y7.25%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y14.75%
Revenue growth 5Y24.17%
Sales Q2Q%-4.85%
Revenue Next Year-3.49%
Revenue Next 2Y-1.07%
Revenue Next 3Y1.05%
Revenue Next 5Y2.36%
EBIT growth 1Y3.81%
EBIT growth 3Y26.12%
EBIT growth 5Y22.99%
EBIT Next Year1.32%
EBIT Next 3Y3.51%
EBIT Next 5Y4.07%
FCF growth 1Y160.15%
FCF growth 3Y15.01%
FCF growth 5Y25.32%
OCF growth 1Y116.49%
OCF growth 3Y15.78%
OCF growth 5Y25.55%